BillionToOne 2025 Q3 Earnings Profitable Turnaround with 138% Net Income Surge

BillionToOne (NASDAQ:BLLN) delivered a strong third-quarter performance in 2025, reporting revenue of $83.52 million—117.4% above the prior year—while returning to profitability with net income of $5.71 million. However, GAAP EPS of $0.10 fell short of the $0.22 consensus, and full-year guidance of $293–299 million revenue (92–96% growth) reflects a conservative yet credible trajectory.

Revenue

The company’s total revenue surged to $83.52 million in Q3 2025, driven by robust performance across segments. Prenatal testing accounted for the lion’s share at $74.07 million, reflecting 102% year-over-year growth. Oncology revenue nearly quintupled to $8.69 million, while clinical trial support services contributed $761,000. This expansion underscores the company’s geographic reach and payer contract gains, as highlighted by CEO Oguzhan Atay.

Earnings/Net Income

BillionToOne’s financial turnaround was stark: net income of $5.71 million in Q3 2025 marked a 138.3% improvement from a $14.90 million loss in 2024. Earnings per share (EPS) rose to $0.14 from a $1.47 loss, signaling a 109.5% positive swing. The EPS miss, however, indicates lingering challenges in meeting investor expectations despite operational success.

Price Action

Post-earnings, the stock edged up 1.67% in the latest trading day, 0.91% over the week, and 3.67% month-to-date. These gains, though modest, align with the company’s broader narrative of profitability and growth.

Post-Earnings Price Action Review

The stock’s post-earnings trajectory reflected mixed signals. While the revenue beat of $0.6 million and net income turnaround bolstered investor confidence, the EPS miss created short-term volatility. Over the week, shares gained 0.91%, with broader market sentiment and sector dynamics influencing the trajectory. Month-to-date, the 3.67% climb suggests gradual stabilization, though the stock remains below its 52-week high of $138.70. Analysts at JPMorgan and Wells Fargo have adjusted price targets, reflecting cautious optimism about the company’s long-term potential.

CEO Commentary

CEO Oguzhan Atay emphasized Q3 as the company’s strongest quarter, with 51% year-over-year test growth and 70% gross margin expansion. Strategic priorities include scaling the Epic partnership for EMR integration and advancing NorthStar Response reimbursement. Atay’s vision of entering the S&P 500 underscores confidence in sustained profitability and market leadership.

Guidance

BillionToOne projects full-year 2025 revenue of $293–299 million (92–96% growth) and Q4 revenue of $84–90 million (86–100% growth). The company expects positive GAAP operating income for both periods, with plans to expand clinical studies for Medicare coverage and develop a pan-cancer MRD test by late 2026.

Additional News

Recent developments include the appointment of Genmab’s CFO Anthony Pagano to the board, effective January 1, 2026, and JPMorgan’s lowered price target to $145 from $150. Additionally, the company’s 10-Q filing revealed $209.1 million in nine-month revenue and $1.5 million net income, reflecting operational efficiency. These moves, alongside strategic partnerships and product launches, position BillionToOne for sustained growth amid competitive pressures.